Navigation Links
Astellas Expands Leadership Team With Senior Vice President of Corporate Strategy and Government Affairs
Date:8/15/2011

DEERFIELD, Ill., Aug. 15, 2011 /PRNewswire/ -- Astellas US, LLC ("Astellas") recently named Percival Barretto-Ko as Senior Vice President, Corporate Strategy and Government Affairs, a new position added to the company's leadership team.  Reporting to President and CEO Masao Yoshida, Barretto-Ko will be responsible for corporate planning, business development, government policy and external affairs and state government affairs.

"This realignment brings key strategic functions closer together at the corporate level," Yoshida said.  "Percival has an outstanding track record both in the pharmaceutical industry and at Astellas' European operations.  He will be a great addition to our senior management team."

Barretto-Ko will move from the position of executive director, corporate strategy and communications at Astellas Pharma Europe Ltd.  While there, he led the global launch of Astellas' new pipeline drug, Advagraf® (tacrolimus prolonged release) in 20 countries. He was promoted to lead the organization's corporate planning function and ultimately directed corporate strategy, corporate planning, corporate communications, crisis management and corporate social responsibility. Prior to joining Astellas, he held increasingly more senior marketing and sales positions with the Roche Group in the United States and United Kingdom. Barretto-Ko earned his undergraduate degree from Cornell University, an MBA from Yale School of Management, and an MS from MIT Sloan School of Management, where he recently served as a Sloan Fellow for Innovation and Global Leadership.

About Astellas

Astellas US LLC, located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas US LLC, please visit our website at www.astellas.us or follow us on Twitter at www.Twitter.com/AstellasUS.


'/>"/>
SOURCE Astellas US, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise
2. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
3. Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary
4. Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile
5. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
6. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
7. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
10. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
11. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 Transparency ... which provides an exhaustive study of the U.S. substance ... 242 companies are functional in this market at ... the leading companies, such as GlaxoSmithKline Plc., Pfizer ... aggressively on various marketing strategies to increase their ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... 2023" report to their offering. ... The ablation device global market is expected ... by 2023. Ablation is the minimally invasive therapeutic ... cancerous or diseased tissue removal, to the removal of abnormally conducting ...
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in 2009 ... have participated in the program every summer. The 2017 Serve, Learn, & Empower ... Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my daughter ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... Rouge, Louisiana (PRWEB) , ... March 29, 2017 ... ... HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers ... at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... this webinar provides insight into the challenges employers face in trying to balance ... of managing employee benefits programs? Adding to the growing complexity, companies are ...
(Date:3/29/2017)... ... 29, 2017 , ... Dr. Angela Cotey, a noted general dentist in Mt. ... patients, with or without a referral. Dr. Cotey knows that interceptive orthodontics ... experience. When patients receive early treatment, they may achieve straight teeth with less treatment ...
Breaking Medicine News(10 mins):